Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria

Pathology and Oncology Research

Volumn 12, Issue 3, 2006, Pages 133-142

  Nagy, Katalin ^a,b   Székely Szüts, Kinga ^d   Izeradjene, Kamel ^d   Douglas, Leslie ^d   Tillman, Mike ^d   Barti Juhász, Helga ^a   Dominici, Massimo ^c   Spano, Carlotta ^c   Cervo, Gian Luca ^c   Conte, Pierfranco ^c   Houghton, Janet A ^d   Mihalik, Rudolf ^a   Kopper, László ^a,b   Peták, István ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Szentágothai János Knowledge Center   (Hungary)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bortezomib PS 341; Colon carcinoma; Epoxomicin; MG132; Smac DIABLO; TRAIL

Indexed keywords

BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 8 INHIBITOR; CYTOCHROME C; DNA FRAGMENT; EPOXOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P17; PROTEIN P20; RECOMBINANT CYTOKINE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; CELL TYPE; COLON CARCINOMA; CONTROLLED STUDY; CYTOSOL; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN EXPRESSION; SENSITIZATION;

EID: 33750865641     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893359     Document Type: Article

References (31)

1. Chaudan D, Hideshima T, Mitsiades C, et al: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4:686-692, 2005
2. Kloetzel PM: The proteasome and MHC class I antigen processing. Biochim Biophys Acta 1695:225-233, 2004
3. Roos-Mattjus P, Sistonen L: The ubiquitin-proteasome pathway. Ann Med 36:285-295, 2004
4. Sun L, Chen ZJ: The novel functions of ubiquitination in signaling. Curr Opin Cell Biol 16:119-126, 2004
5. Mani A, Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23:4776-4789, 2005
6. Petak I, Vernes R, Szucs KS, et al: A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells. Cell Death Differ 10:729-739, 2003
7. Petak I, Houghton JA: Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 7:95-106, 2001
8. Petak I, Douglas L, Tillman DM, et al: Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 6:4119-4127, 2000
9. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-237, 2005
10. Guseva NV, Taghiyev AF, Sturm MT, et al: Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines. Mol Cancer Res 2:574-584, 2004
11. Aggarwal BB, Bhardwaj U, Takada Y: Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 67:453-483, 2004
12. Yang LQ, Fang DC, Wang RQ, Yang SM: Effect of NF-kappaB, survivin, Bcl-2 and caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 10:22-25, 2004
13. Bortul R, Tazzari PL, Cappelllni A, et al: Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 17:379-89, 2003
14. Ehrhardt H, Fulda S, Schmid I, et al: TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22:3842-3852, 2003
15. Franco AVZhang XD, Van Berkel E, et al: The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166:5337-5345, 2001
16. Jeremias I, Kupatt C, Baumann B, et al: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 91:4624-4631, 1998
17. Johnson TR, Stone K, Nikrad M, et al: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22:4953-4963, 2003
18. Zhu H, Guo W, Zhang L, et al: Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 4:781-786, 2005
19. Zhu H, Zhang L, Dong F, et al: Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 24:4993-4999, 2005
20. Nikrad M, Johnson T, Puthalalath H, et al: The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 4:443-449, 2005
21. Schneider P: Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 322:325-3245, 2000
22. Leverkus M, Sprich MR, Wachter T, et al: Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23:777-790, 2003
23. Chauhan D, Li G, Podar K, et al: Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 104:2458-2466, 2004
24. LaVallee TM, Zhan XH, Johnson MS, et al: 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63:468-475, 2003
25. Creagh EM, Murphy BM, Duriez PJ, et al: Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J Biol Chem 279:26906-26914, 2004
26. Du C, Fang M, Li Y, et al: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42, 2000
27. Ni H, Ergin M, Huang Q, et al: Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115:279-286, 2001
28. Berenson JR, Ma HM, Vescio K: The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28:626-633, 2001
29. Tillman DM, Izeradjene K, Szucs KS, et al: Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res 63:5118-5125, 2003
30. Ganten TM, Koschny R, Haas TL, et al: Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42:588-597, 2005
31. Lashinger LM, Zhu K, Williams SA, et al: Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65:4902-4908, 2005